A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 May 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 01 May 2017 Planned primary completion date changed from 1 Dec 2016 to 15 Jan 2021.
- 04 May 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.